BidaskClub upgraded shares of Clearside Biomedical (NASDAQ:CLSD) from a sell rating to a hold rating in a research note issued to investors on Friday.
A number of other research analysts also recently weighed in on CLSD. JMP Securities reaffirmed an outperform rating and issued a $25.00 target price on shares of Clearside Biomedical in a research report on Monday, March 5th. JPMorgan Chase & Co. reissued an overweight rating and issued a $18.00 price objective (up previously from $15.00) on shares of Clearside Biomedical in a research report on Tuesday, March 6th. Zacks Investment Research downgraded shares of Clearside Biomedical from a hold rating to a sell rating in a research report on Monday, November 13th. Needham & Company LLC lifted their price objective on shares of Clearside Biomedical from $18.00 to $22.00 and gave the company a buy rating in a research report on Tuesday, March 6th. Finally, ValuEngine downgraded shares of Clearside Biomedical from a sell rating to a strong sell rating in a research report on Monday, February 5th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $19.50.
Clearside Biomedical (NASDAQ CLSD) opened at $12.64 on Friday. The firm has a market cap of $320.33 and a price-to-earnings ratio of -6.58. Clearside Biomedical has a 12-month low of $5.30 and a 12-month high of $15.06. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.57 and a quick ratio of 4.57.
COPYRIGHT VIOLATION WARNING: “Clearside Biomedical (CLSD) Raised to Hold at BidaskClub” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://sportsperspectives.com/2018/03/13/clearside-biomedical-clsd-raised-to-hold-at-bidaskclub.html.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.